Price target lowered from $16 to $6 by Wedbush: Wedbush downgraded XenoPort and lowered its price target for shares to $6 from $16 after Arbaclofen Placarbil failed in a Phase III trial for multiple sclerosis spasticity.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.